| For: | Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. World J Gastroenterol 2019; 25(23): 2839-2845 [PMID: 31249443 DOI: 10.3748/wjg.v25.i23.2839] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i23/2839.htm |
| Number | Citing Articles |
| 1 |
Ruchi Singhal, Sherise C Rogers, Ji-Hyun Lee, Brian Ramnaraign, Ilyas Sahin, Jesus C Fabregas, Ryan M. Thomas, Steven J Hughes, Ibrahim Nassour, Kathryn Hitchcock, Karen Russell, Omar Kayaleh, Anita Turk, Robert Zlotecki, David L DeRemer, Thomas J George. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Future Oncology 2023; 19(27) doi: 10.2217/fon-2023-0256
|
| 2 |
Xiangsheng Liu, Jinhong Jiang, Yu‐Pei Liao, Ivanna Tang, Emily Zheng, Waveley Qiu, Matthew Lin, Xiang Wang, Ying Ji, Kuo‐Ching Mei, Qi Liu, Chong Hyun Chang, Zev A. Wainberg, Andre E. Nel, Huan Meng. Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1. Advanced Science 2021; 8(6) doi: 10.1002/advs.202002147
|
| 3 |
Antonio Galvano, Marta Castiglia, Sergio Rizzo, Nicola Silvestris, Oronzo Brunetti, Giovanni Vaccaro, Valerio Gristina, Nadia Barraco, Marco Bono, Giovanni Guercio, Giuseppa Graceffa, Fabio Fulfaro, Stefania Gori, Viviana Bazan, Antonio Russo. Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. Cancers 2020; 12(3) doi: 10.3390/cancers12030534
|
| 4 |
Jae Yun Jung, Hyun Jin Ryu, Seung-Hwan Lee, Dong-Young Kim, Myung Ji Kim, Eun Ji Lee, Yeon-Mi Ryu, Sang-Yeob Kim, Kyu-Pyo Kim, Eun Young Choi, Hyung Jun Ahn, Suhwan Chang. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Cells 2021; 10(10) doi: 10.3390/cells10102734
|
| 5 |
Xiao Wang, Yueqin Zhang, Anan Li, Chuanzan Zhou, Sen Xu, Zongting Gu, Wei Wang, Peng Nan, Ran Tao. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Journal of Gastroenterology 2025; 60(11) doi: 10.1007/s00535-025-02291-3
|
| 6 |
TUĞBA AKMAN YILDIZ, EMEK KÖSE, SAMANTHA L. ELLIOTT. MATHEMATICAL MODELING OF PANCREATIC CANCER TREATMENT WITH CANCER STEM CELLS. Journal of Biological Systems 2021; 29(04) doi: 10.1142/S0218339021500182
|
| 7 |
Taylor J. Allen-Coyle, Jin Niu, Eva Welsch, Neil T. Conlon, Weylon Garner, Martin Clynes, Finbarr O’Sullivan, Robert M. Straubinger, Donald E. Mager, Sandra Roche. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. The AAPS Journal 2022; 24(6) doi: 10.1208/s12248-022-00752-8
|
| 8 |
Amir Ashraf Ganjouei, Jane Wang, Sophia Hernandez, Laleh Foroutani, Fernanda Romero Hernandez, Kenzo Hirose, Eric Nakakura, Carlos Corvera, Adnan Alseidi, Mohamed Abdelgadir Adam. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Annals of Surgical Oncology 2026; doi: 10.1245/s10434-026-19829-1
|
| 9 |
Richard Drexler, Kim C. Wagner, Mirco Küchler, Bernd Feyerabend, Moritz Kleine, Karl J. Oldhafer. Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2020; 146(5) doi: 10.1007/s00432-020-03175-0
|
| 10 |
Shintaro Fumoto, Koyo Nishida. Co-delivery Systems of Multiple Drugs Using Nanotechnology for Future Cancer Therapy. Chemical and Pharmaceutical Bulletin 2020; 68(7) doi: 10.1248/cpb.c20-00008
|